

In clinical oncology, Molecular Diagnostics have numerous applications. Mutation analysis is now used routinely to diagnose hereditary cancer syndromes. Tight medical surveillance and various preventive interventions benefit healthy carriers of cancer-predisposing mutations. Cancers caused by germ-line mutations frequently necessitate significant changes in treatment strategy. Personalized cancer drug selection based on the presence of actionable mutations has become an essential component of cancer therapy. Molecular tests underpin the use of EGFR, BRAF, ALK, ROS1, PARP inhibitors, as well as other cytotoxic and targeted drugs. Tumor fragments (single cells or clusters, DNA, RNA, proteins) are almost always shed into various body fluids.
Read More:
Click here for Molecular Diagnostics Market Report:
https://www.coherentmarketinsights.com/market-insight/molecular-diagnostics-market-1545
Click here for Molecular Diagnostics Market Press Release:





